LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager

Colorectal cancer (CRC) is one of the most common cancers worldwide and demands more effective treatments. We sought to identify tumor selective CRC antigens and their therapeutic potential for cytotoxic T-cell targeting by transcriptomic and immunohistochemical analysis. LY6G6D was identified as a...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrales, Leticia, Hipp, Susanne, Martin, Katharina, Sabarth, Nicolas, Tirapu, Iñigo, Fuchs, Klaus, Thaler, Barbara, Walterskirchen, Christian, Bauer, Kathrin, Fabits, Markus, Bergmann, Michael, Binder, Carina, Chetta, Paolo ML., Vogt, Anne B., Adam, Paul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493073/
https://www.ncbi.nlm.nih.gov/pubmed/36159851
http://dx.doi.org/10.3389/fimmu.2022.1008764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9493073/
https://www.ncbi.nlm.nih.gov/pubmed/36159851
http://dx.doi.org/10.3389/fimmu.2022.1008764

Ejemplares similares